| Methods |
4‐week single‐blind placebo baseline; inclusion criteria= sitting DBP 95‐115 mm Hg; 8‐week double‐blind treatment |
| Participants |
All patients: n=707(457 males,250 females); mean age=53.5(10.5) years; baseline sitting SBP=155.5(17.7) mm Hg, DBP=101.9(5.7) mm Hg;
Enalapril 5 mg: n=85;
Enalapril 20 mg: n=48;
Placebo: n=79 |
| Interventions |
Enalapril 5 mg once daily;
Enalapril 20 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported; SD of change not reported; endpoint BP and SD not reported; baseline SBP SD for all groups reported; imputed baseline SBP SD for SD of change; imputed systematic review overall mean SD of change for DBP; DBP data from Figure 1, p. 432; SBP data from Figure 2, p. 433; Jadad score=3; funding source= Astra Merck, Inc. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
